SCG Cell Therapy Presented New Preclinical Data in an Oral Presentation at ASGCT 2024 Annual Meeting Highlighting Superior Tumor Inhibition of its Immunoswitch Armored HPV-TCR T Cell Therapy (SCG142) against a Broad Range of HPV-associated Cancers

SINGAPORE, May 12, 2024 /PRNewswire/ — SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced first preclinical data of its novel human papillomavirus (HPV)-specific T cell…